Bifogade filer
BONESUPPORT Q1 2025 EN
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från BONESUPPORT Holding AB (publ) via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2025-04-24 08:00:00
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2025.
STRONG GROWTH AND CASH FLOW – CURRENCY SWINGS IMPACTING REPORTED EARNINGS
"Strong growth driven by solid market penetration." Emil Billbäck, CEO
JANUARY - MARCH 2025
- Net sales increased by 54 percent (50 percent at constant exchange rates) and amounted to SEK 283.5 million (184.4).
- The North America (NA) segment reported a sales growth of 63 percent (59 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 22 percent (21 percent at constant exchange rates).
- The gross margin amounted to 92.6 percent (92.6).
- The adjusted operating result amounted to SEK 39.7 million (41.6). The reported operating result amounted to SEK 29.6 million (32.3).
- Earnings per share before and after dilution were SEK 0.16 (0.33).
EVENTS DURING THE QUARTER
- As a result of the Swedish krona strengthening against both the USD, EUR and GBP in the quarter, with the greatest strengthening and effect related to the USD, operating profit was impacted with currency translation effects amounting to a negative SEK 30.4 million, of which SEK 27.6 million is unrealized.
- In January, a clinical study including 105 diabetes patients with bone infection in the foot, was reported, that showed that treatment with CERAMENT G or CERAMENT V gave significant advantages compared to standard treatment. The results showed improved infection healing and a dramatic improvement in survival rate to 87.5 percent compared to 44.9 percent in the standard treatment group, over a five-year period.
- At the end of March, the Company submitted market authorization application for its antibiotic eluting bone graft substitute, CERAMENT V in the US, with the Food and Drug Administration (FDA), for the indication bone infection.
EVENTS AFTER THE PERIOD
- The US Centers for Medicare & Medicaid Services (CMS) recommends NTAP of USD 5,688 for CERAMENT G and the indication open fractures. A final decision is expected in August 2025.
- CMS recommends a substantial increase in reimbursements for orthopedic procedures in extremities in inpatient care by 6 percent for 2026. A final decision is expected in August 2025.